biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by rustycaton Jun 18, 2014 11:09pm

183 Views

Post# 22673744

RE:Financials and MD&A Released

Interesting to note that UCB Pharma will be presenting at the European Healthcare Conference Jun 26, 2014 London, UK J.P. Morgan offices, 25 Bank Street . Of course one has to wonder if it is a coincidence that BTI just posted their beautiful corporate update/presentation, 10 days prior to the conference.

Bullboard Posts

Rich TV Live’s Stocks to Watch this week (Nov. 15, 2024)